[ALKS] Alkermes plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 57.99 Change: 1.68 (2.98%)
Ext. hours: Change: 0 (0%)

chart ALKS

Refresh chart

Strongest Trends Summary For ALKS

ALKS is in the medium-term down -41% below S&P in 6 months. In the long-term down -59% in 2 years and down -73% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a

Fundamental Ratios
Shares Outstanding EPS-1.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.08% Sales Growth - Q/Q-7.96% P/E-43.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.89% ROE-2.56% ROI-2.04%
Current Ratio8.79 Quick Ratio8.36 Long Term Debt/Equity0.39 Debt Ratio0.08
Gross Margin72.77% Operating Margin-15.17% Net Profit Margin-5.6% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.94 M Cash From Investing Activities-31.78 M Cash From Operating Activities-13.33 M Gross Profit120.95 M
Net Profit-46.11 M Operating Profit-52.52 M Total Assets1.91 B Total Current Assets1.02 B
Total Current Liabilities134.22 M Total Debt354.81 M Total Liabilities515.68 M Total Revenue151.37 M
Technical Data
High 52 week61.63 Low 52 week24.85 Last close24.85 Last change-1.78%
RSI9.78 Average true range1.04 Beta1.3 Volume502.8 K
Simple moving average 20 days-13.22% Simple moving average 50 days-22.94% Simple moving average 200 days-36.99%
Performance Data
Performance Week-5.51% Performance Month-25.06% Performance Quart-31.73% Performance Half-44.17%
Performance Year-57.8% Performance Year-to-date-29.22% Volatility daily3.38% Volatility weekly7.57%
Volatility monthly15.51% Volatility yearly53.73% Relative Volume195.73% Average Volume1.08 M
New High New Low

News

2019-09-13 19:15:04 | Alkermes Plc ALKS Director and CEO, Alkermes plc Richard F Pops Sold $2.3 million of Shares

2019-09-13 07:00:00 | Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

2019-09-06 18:15:14 | Alkermes Plc ALKS Director and CEO, Alkermes plc Richard F Pops Sold $2 million of Shares

2019-08-24 09:31:01 | Why Is Alkermes ALKS Down 3.9% Since Last Earnings Report?

2019-08-19 14:19:43 | An Intrinsic Calculation For Alkermes plc NASDAQ:ALKS Suggests It's 49% Undervalued

2019-08-02 10:04:02 | Clovis CLVS Q2 Earnings & Sales Lag Estimates, Shares Down

2019-07-31 11:36:03 | Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

2019-07-30 15:05:00 | Biogen Hedged Its Bet and Won Big

2019-07-30 07:30:00 | Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

2019-07-29 12:30:00 | Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

2019-07-26 13:45:00 | Alkermes Bounces Back -- but Not Enough

2019-07-26 10:38:02 | Alkermes ALKS Earnings and Sales Beat Estimates in Q2

2019-07-26 07:26:37 | The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

2019-07-26 00:03:46 | Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT

2019-07-25 17:23:30 | Alkermes PLC ALKS Q2 2019 Earnings Call Transcript

2019-07-25 08:55:12 | Alkermes ALKS Beats Q2 Earnings and Revenue Estimates

2019-07-25 07:21:54 | The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

2019-07-25 07:00:00 | Alkermes Plc Reports Second Quarter 2019 Financial Results

2019-07-18 16:01:00 | Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results

2019-07-18 11:23:20 | Does Alkermes plc NASDAQ:ALKS Have A Particularly Volatile Share Price?

2019-07-18 10:32:02 | Earnings Preview: Alkermes ALKS Q2 Earnings Expected to Decline

2019-07-17 10:06:02 | Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

2019-07-17 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?

2019-07-16 09:36:01 | Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

2019-07-15 07:00:00 | Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

2019-07-01 07:00:00 | Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History

2019-06-25 09:30:01 | CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

2019-06-18 15:42:13 | Did You Manage To Avoid Alkermes's NASDAQ:ALKS Painful 56% Share Price Drop?

2019-06-18 08:06:55 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-15 08:07:34 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

2019-06-13 08:06:46 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-12 07:00:00 | Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

2019-06-11 11:04:05 | Here’s What Hedge Funds Think About Alkermes Plc ALKS

2019-06-11 08:08:20 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-10 08:07:53 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-08 08:12:57 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-06 09:30:01 | CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

2019-06-06 08:08:01 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-06-04 08:08:27 | See what the IHS Markit Score report has to say about Alkermes Plc.

2019-05-31 09:07:01 | Biogen Reports Interim Phase III Data on Diroximel Fumarate

2019-05-30 07:30:00 | New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

2019-05-29 10:34:02 | Allergan's AGN Vraylar Gets FDA Nod for Bipolar Depression

2019-05-25 09:31:01 | Why Is Alkermes ALKS Down 21% Since Last Earnings Report?

2019-05-22 11:34:56 | Does Alkermes plc's NASDAQ:ALKS CEO Salary Compare Well With Others?

2019-05-22 07:00:00 | Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

2019-05-16 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?

2019-05-14 16:01:00 | Alkermes to Present at the UBS Global Healthcare Conference

2019-05-13 07:00:00 | Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

2019-05-07 08:05:51 | See what the IHS Markit Score report has to say about Alkermes Plc.